You are here:     > Corporate Overview > Glenmark at a glance

Glenmark at a glance

Glenmark Dahej Team

In the last 40 years, Glenmark has grown from an India-based organisation with a single dermatology product to a global pharmaceutical company. Today, it has more than 6,000 products worldwide that include offerings in Respiratory, Dermatology and Oncology therapeutic areas.

Glenmark’s manufacturing facility at Monroe, North Carolina, USA

    Our Vision    

To emerge as a leading integrated research-led global pharmaceutical company

At Glenmark, we began investing in our innovation programme over a decade ago. Our innovation venture has begun to deliver results with new molecules, currently in different stages of development, in the three focus areas of Respiratory, Dermatology and Oncology. We have not only evolved into a successful global branded generics organisation, but have also built a reputation of being an innovation-driven organisation in a space dominated by global pharmaceutical giants.

We have expanded our manufacturing footprint to 16 facilities in four continents and augmented our international operations to build a strong presence globally. The innovative pipeline of Novel Molecular Entities (NMEs) and Specialty Products, built by our scientists in six R&D centres in India, Switzerland and the US, differentiates us from our peers.

We have enriched the lives of millions of patients over the past 40 years by offering them safe and affordable medication. We have evolved into a USD 1.4 Bn global pharmaceutical organisation with over 13,500 employees in 50 countries, deriving more than 70% of our revenues from international markets.

Our Business Divisions

Our business is primarily structured into Branded and Generic Formulations, Active Pharmaceutical Ingredients (APIs), and Novel Molecular Entities (NMEs) & Specialty Products.

1 Additional therapies in some markets like cardio-metabolic in India and CNS in Central and Eastern Europe (CEE)

2 Commonwealth of Independent States